SEARCH

SEARCH BY CITATION

References

  • Abello N., Kerstjens H. A., Postma D. S. and Bischoff R. (2009) Protein tyrosine nitration: selectivity, physicochemical and biological consequences, denitration, and proteomics methods for the identification of tyrosine-nitrated proteins. J. Proteome Res. 8, 32223238.
  • Adam-Vizi V. (2005) Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. Antioxid. Redox Signal. 7, 11401149.
  • Bo S., Gambino R., Guidi S., Silli B., Gentile L., Cassader M. and Pagano G. F. (2005) Plasma nitrotyrosine levels, antioxidant vitamins and hyperglycaemia. Diabet. Med. 22, 11851189.
  • Candelario-Jalil E., Yang Y. and Rosenberg G. A. (2009) Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 158, 983994.
  • Castellanos M., Sobrino T., Millan M. et al. (2007) Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke 38, 18551859.
  • Chen H., Yoshioka H., Kim G. S. et al. (2011) Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid. Redox Signal. 14, 15051517.
  • Cho A. H., Suh D. C., Kim G. E., Kim J. S., Lee D. H., Kwon S. U., Park S. M. and Kang D. W. (2009) MRI evidence of reperfusion injury associated with neurological deficits after carotid revascularization procedures. Eur. J. Neurol. 16, 10661069.
  • Chou S. H., Feske S. K., Simmons S. L. et al. (2011) Elevated peripheral neutrophils and matrix metalloproteinase 9 as biomarkers of functional outcome following subarachnoid hemorrhage. Transl. Stroke Res. 2, 600607.
  • Chrissobolis S. and Faraci F. M. (2008) The role of oxidative stress and NADPH oxidase in cerebrovascular disease. Trends Mol. Med. 14, 495502.
  • Cuadrado E., Ortega L., Hernandez-Guillamon M., Penalba A., Fernandez-Cadenas I., Rosell A. and Montaner J. (2008) Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. J. Leukoc. Biol. 84, 207214.
  • Donnan G. A., Davis S. M., Parsons M. W., Ma H., Dewey H. M. and Howells D. W. (2011) How to make better use of thrombolytic therapy in acute ischemic stroke. Nat. Rev. Neurol. 7, 400409.
  • Fraser P. A. (2011) The role of free radical generation in increasing cerebrovascular permeability. Free Radical Biol. Med. 51, 967977.
  • Guix F. X., Uribesalgo I., Coma M. and Munoz F. J. (2005) The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol. 76, 126152.
  • Gursoy-Ozdemir Y., Bolay H., Saribas O. and Dalkara T. (2000) Role of endothelial nitric oxide generation and peroxynitrite formation in reperfusion injury after focal cerebral ischemia. Stroke 31, 19741980 ; discussion 1981.
  • Gursoy-Ozdemir Y., Can A. and Dalkara T. (2004) Reperfusion-induced oxidative/nitrative injury to neurovascular unit after focal cerebral ischemia. Stroke 35, 14491453.
  • Hadler-Olsen E., Fadnes B., Sylte I., Uhlin-Hansen L. and Winberg J. O. (2011) Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 278, 2845.
  • Hall C. N. and Garthwaite J. (2009) What is the real physiological NO concentration in vivo? Nitric Oxide 21, 92103.
  • Heo J. H., Lucero J., Abumiya T., Koziol J. A., Copeland B. R. and del Zoppo G. J. (1999) Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J. Cereb. Blood Flow Metab. 19, 624633.
  • Heo J. H., Kim S. H., Lee K. Y., Kim E. H., Chu C. K. and Nam J. M. (2003) Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroke 34, e4850.
  • Horstmann S., Kalb P., Koziol J., Gardner H. and Wagner S. (2003) Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 34, 21652170.
  • Jian Liu K. and Rosenberg G. A. (2005) Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic. Biol. Med. 39, 7180.
  • Jin H., Webb-Robertson B. J., Peterson E. S., Tan R., Bigelow D. J., Scholand M. B., Hoidal J. R., Pounds J. G. and Zangar R. C. (2011) Smoking, COPD, and 3-nitrotyrosine levels of plasma proteins. Environ. Health Perspect. 119, 13141320.
  • Kahles T., Luedike P., Endres M., Galla H. J., Steinmetz H., Busse R., Neumann-Haefelin T. and Brandes R. P. (2007) NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke 38, 30003006.
  • Kouwenhoven M., Carlstrom C., Ozenci V. and Link H. (2001) Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke. J. Clin. Immunol. 21, 365375.
  • Lu A., Clark J. F., Broderick J. P., Pyne-Geithman G. J., Wagner K. R., Ran R., Khatri P., Tomsick T. and Sharp F. R. (2008) Reperfusion activates metalloproteinases that contribute to neurovascular injury. Exp. Neurol. 210, 549559.
  • Marchesi C., Dentali F., Nicolini E. et al. (2012) Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J. Hypertens. 30, 316.
  • Miller A. A., Drummond G. R., De Silva T. M., Mast A. E., Hickey H., Williams J. P., Broughton B. R. and Sobey C. G. (2009) NADPH oxidase activity is higher in cerebral versus systemic arteries of four animal species: role of Nox2. Am. J. Physiol. Heart Circ. Physiol. 296, H220225.
  • Montaner J. (2006) Stroke biomarkers: can they help us to guide stroke thrombolysis? Drug News Perspect. 19, 523532.
  • Montaner J., Alvarez-Sabin J., Molina C., Angles A., Abilleira S., Arenillas J., Gonzalez M. A. and Monasterio J. (2001) Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32, 17591766.
  • Montaner J., Fernandez-Cadenas I., Molina C. A. et al. (2003) Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene. Stroke 34, 28512855.
  • van Mook W. N., Rennenberg R. J., Schurink G. W., van Oostenbrugge R. J., Mess W. H., Hofman P. A. and de Leeuw P. W. (2005) Cerebral hyperperfusion syndrome. Lancet neurol. 4, 877888.
  • Nagashima T., Wu S., Ikeda K. and Tamaki N. (2000) The role of nitric oxide in reoxygenation injury of brain microvascular endothelial cells. Acta Neurochir. Suppl. 76, 471473.
  • Ning M., Furie K. L., Koroshetz W. J. et al. (2006) Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology 66, 15501555.
  • Ohta K., Graf R., Rosner G. and Heiss W. D. (1997) Profiles of cortical tissue depolarization in cat focal cerebral ischemia in relation to calcium ion homeostasis and nitric oxide production. J. Cereb. Blood Flow Metab. 17, 11701181.
  • Pacher P., Beckman J. S. and Liaudet L. (2007) Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87, 315424.
  • Peluffo G. and Radi R. (2007) Biochemistry of protein tyrosine nitration in cardiovascular pathology. Cardiovasc. Res. 75, 291302.
  • Ramos-Fernandez M., Bellolio M. F. and Stead L. G. (2011) Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J. Stroke Cerebrovasc. Dis. 20, 4754.
  • Rosell A. and Lo E. H. (2008) Multiphasic roles for matrix metalloproteinases after stroke. Curr. Opin. Pharmacol. 8, 8289.
  • Rosell A., Cuadrado E., Ortega-Aznar A., Hernandez-Guillamon M., Lo E. H. and Montaner J. (2008) MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 39, 11211126.
  • Rosenberg G. A., Navratil M., Barone F. and Feuerstein G. (1996) Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J. Cereb. Blood Flow Metab. 16, 360366.
  • Shishehbor M. H., Aviles R. J., Brennan M. L. et al. (2003) Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 289, 16751680.
  • Snoek-van Beurden P. A. and Von den Hoff J. W. (2005) Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 38, 7383.
  • Sood R. R., Taheri S., Candelario-Jalil E., Estrada E. Y. and Rosenberg G. A. (2008) Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J. Cereb. Blood Flow Metab. 28, 431438.
  • Thomalla G., Sobesky J., Kohrmann M. et al. (2007) Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke 38, 313318.
  • Tsuji K., Aoki T., Tejima E. et al. (2005) Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 36, 19541959.
  • Wahlgren N., Ahmed N., Davalos A. et al. (2007) Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369, 275282.
  • Wei G., Dawson V. L. and Zweier J. L. (1999) Role of neuronal and endothelial nitric oxide synthase in nitric oxide generation in the brain following cerebral ischemia. Biochim. Biophys. Acta 1455, 2334.
  • Yang Y., Estrada E. Y., Thompson J. F., Liu W. and Rosenberg G. A. (2007) Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J. Cereb. Blood Flow Metab. 27, 697709.
  • Yemisci M., Gursoy-Ozdemir Y., Vural A., Can A., Topalkara K. and Dalkara T. (2009) Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat. Med. 15, 10311037.
  • Yepes M., Roussel B. D., Ali C. and Vivien D. (2009) Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci. 32, 4855.
  • Zhao B. Q., Tejima E. and Lo E. H. (2007) Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke 38, 748752.